Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PD should start this year as you said. The trial should be only 3 months per Missling. If we expect RTT results next year we should also expect PD results.
At some point they will notice. Then you can kiss these low prices goodbye.
Monday morning??
More awesome news today. Should see start of trials very soon now.
Every PR from the company continues to impress. Just need mainstream to take notice. We’re flying too fast and too high for most to grasp our success. Soon, though, we will dominate the CNS space.
Or Monday. We’ll see.
Takes you to old data from October.
I doubt we will get any info till Monday morning.
Looks like Missling’s purchases have ended...
Time to rock and roll.
Will our pps surpass AXON today? Universe moving closer to making sense.
Monday morning PR going to be great!!
They have waited till Monday morning in the past and I expect it again this time. The oral presentation isn’t till Saturday so there is no legal need to release till Monday since markets are closed.
AVXL is just getting ready to begin three new trials. There aren’t any results scheduled for release before that happens.
Q:
How could it fail in the short-term?
A:
It can’t. Nothing but pure positive catalysts with virtually no chance of negative news through the end is the year.
If I hear this again without actions I’m going to be sick:
“These findings are very encouraging and support our strategy to initiate a randomized and placebo-controlled Phase 2 study”
- Missling
START A NEW TRIAL NOW!!!!!
Source:
https://parkinsonsnewstoday.com/2017/10/31/anavex-2-73-investigational-therapy-restored-nerve-cell-function-in-mice-with-parkinsons-disease-in-lab-study/
Great!
These are details of the already-known fact that it showed promise in the mouse model studies. Already has been factored into the pps.
Confirm it please AVXL. Start the trials.
From the PR 9/22/16:
“The data indicates that ANAVEX 2-73 is well tolerated, induces significant motor recovery (p<0.05), induces neurohistological restoration (p<0.05) and reduces microglial activation (p<0.05)”
From the previously released poster for today’s presentation:
“ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism “
Not exact same words, but same meaning.
Don’t get me wrong... glad to hear the results are good, but I already knew that based on previous info. And it’s preclinical mouse model data. Good indicator, but won’t amount to much till trials start and readouts show good results.
Note the pps right now is up a measly 11 cents. Hope it goes higher today, but not holding my breath for anything huge.
They have used that wording before.
The poster title basically says everything the PR said.
“ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism “
STOP DILLY DALLYING AND START THE TRIALS!!
This was already known before today.
Don’t really see anything new in the PR.
Absolutely conclusive evidence on a personal basis for the 25 participants. No one has ever been able to improve over a 1-year period. EVER.
You can try to marginalize the results as much as you want, but facts are facts. They’re stubborn little things.
When the current approved drugs went through their approval trials there were ZERO participants who improved. As has been pointed out by AVXL’s SAB, this has never happened with any medication (approved or not) in history.
You can say that the improved patients aren’t a big enough group to claim “statistical significance”.
You can say that the trial has no placebo.
That’s fine... but some patients improved and that is great no matter how you cut it. It means a bigger trial is absolutely justified and will happen.
Just saying.
Pie in the sky delusions of BP deals... while back in reality we struggle to hold onto +$4.
Sounding like a broken record playing a sad song.
Maybe we should set a goal of getting over 5 bucks before we start claiming that a BP deal is imminent.
Nothing is going to move the pps upwards till interim readouts are PR’d from the 2/3 AD trial.
START THE TRIALS...for the love of God!!!
What a great time to get into AVXL!
Cluster of HUGE and guaranteed-to-be-positive catalysts to be delivered in next 9 weeks.
Nothing will be able to stop the panic buying of the Shorts, the profiting of the Longs, the humiliation of Fartstein... and certainly no way to wipe the grin off this Longs face!!
There is more of a likelihood of BIIB being interested in the MS application for 2-73 than AD.
I don’t think BIIB is going to make an offer for AVXL. I would be very happy to be wrong about that. And I certainly wouldn’t be shocked if it happened.
Better to not set your sights too high and risk disappointment. For right now, looking forward to guaranteed positive catalysts for the rest of the year.
Data looks amazing. Statistically significant and every update seems to be better than the last.
Can’t wait for the three trials to start before end of December 2017.
That’s a lot of major, positive catalysts in a very short timeframe.
The best part is that the upcoming catalysts can’t be twisted or distorted to show something negative. Starting a trial is always good. Very little possibility of negative news through end of year.
Go AVXL!!
Well have to agree to disagree. I heard what he said and I understand him to have said “No partner, and no dilution.”
Everyone is entitled to their own opinion. I try to keep my personal wants and desires out of my analysis as much as I can. I would love to see a quick jump in pps from a partnership. Based on what he said in response to the question asked I don’t see that as a short term goal for Missling.
He was asked how are you going to fund these trials. Answer: we already have the money needed.
As I said, MS may be another story. Maybe a licensing deal is possible. Maybe a partnership. Missling didn’t address MS at all. The answer he gave was specifically for AD, PD & RTT.
I’m not betting on a deal at this time though.
I agree. MS is the wild card
Near the end. During questions and answers.
You are incorrect. There was one question. (Paraphrasing) “Do you need more money at this time?” He then have examples of how those funds might be raised. He suggested either dilution or partnering, for example.
Missling’s answer addressed everything he asked about. Missling said (paraphrasing) “We have enough cash to fund all the trials we have planned. We do not need to raise any more cash. We don’t need to do either of those things you suggested. No dilution and no partnering needed right now.”
HE IS SAYING NO PARTNER AT THIS TIME.
I realize many had built up the idea in their minds like it was a done deal. But the reality, according to Missling, is that it isn’t happening at this time.
Maybe that will change, but there is no reason to keep expecting it in the short term.
AVXL looking great heading into good news on top of good news in next couple weeks.
Nobody can come up with solid reasons for skepticism, other than the good advice of “be careful with biotech’s”. Which is true by the way.
Nothing foreseeable at this point will derail us. Looking forward to upcoming trial launches.
Hold on tight! (To your butts and your shares)
You are pretty much on your own with that assessment of those three distinguished researchers. You’re starting to embarrass yourself now.
I’m not sure what your basis is for asserting deeper understanding and familiarity with the dynamics involved than the three doctors who participated in the recent PK/PD conference call?
Is there some data that has eluded all the rest of us including the three doctors who put their reputations on the line?
I think we have a legitimate chance of approval at the 6-month readout if the results of the 2/3 are comparable to the results we saw in 2a.
Getting pretty interesting with those $5 calls expiring today...
Do we know anything about the presenter, F. Pellegrini?
Any connection to AVXL or 2-73?
I disagree.
When the 2/3 AD trial begins it will be a significant event for a few reasons.
Many investors and institutions have held off from investing until phase 3. For many this is a rule, be it personal or professional.
Also, one of the major knocks against AVXL this far has been its lack of a control arm and small sample size. The 2/3 trial will negate these (IMO) low-information opinions.
Also, as the 2/3 gets toward its first interim readout (say, around May-ish 2018) we should see RTT results. This (if good) will be a tremendous boost to the pps.
So... PR tomorrow regarding start of RTT trial??
AD trial should be preceded by RTT trial start AND PD trial start per relatively recent comments by Missling. He said PK/PD would come before anything else and it happened.
Next big news will be RTT trial start.
Not saying AD can't start by 11/4/17, but whenever it is, it will be after RTT and PD trials have started.
All this is IMO based on Missling's words and prior presentations/slides.